Biologics Regulatory Spine Ventris Medical Receives Additional FDA Clearance for Backpack® Bone Graft in the Intervertebral Disc Space byJosh SandbergApril 8, 2025
Spine Top Stories NGMedical Announces Australian TGA Approval For MOVE®-C Cervical Artificial Disc byJosh SandbergMarch 19, 2025
Financial Spine Prosthetic Disc Nucleus Market Set to Reach $265.8 Million by 2034, TMR Forecasts 8.2% CAGR – TMR Insights byJosh SandbergJanuary 28, 2025
Spine Centinel Spine® to Sponsor Major Worldwide Live Webinar Symposium on Cervical Disc Arthroplasty byTim AllenMarch 21, 2024
Spine Five-Year Study Outcomes of the NuVasive Simplify Cervical Disc were Presented at the North American Spine Society 38th Annual Meeting byJosh SandbergOctober 24, 2023
Spine Orthofix Announces Presentation of Long-Term Evidence Highlighting the Clinical Management of Cervical Disc Arthroplasty at North American Spine Society Annual Meeting byChris StewartOctober 10, 2022
Financial Spine Artificial Cervical Intervertebral Disc Market Size Worth $4.37 Bn Globally, by 2028 at 18.0% CAGR – Exclusive Report by The Insight Partners byJosh SandbergJuly 25, 2022
Biologics Spine BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD) byChris StewartJune 30, 2022
Biologics Spine BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD) byChris StewartJune 22, 2022
Biologics Spine BioRestorative Therapies Announces Clinical Site Initiation for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD) byJosh SandbergJune 13, 2022
